S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:HUMA

Humacyte (HUMA) Stock Price, News & Analysis

$4.33
+0.03 (+0.70%)
(As of 02/23/2024 ET)
Today's Range
$4.14
$4.38
50-Day Range
$2.57
$4.84
52-Week Range
$1.96
$5.60
Volume
345,706 shs
Average Volume
656,809 shs
Market Capitalization
$448.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.75

Humacyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
79.0% Upside
$7.75 Price Target
Short Interest
Bearish
8.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Humacyte in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.94) to ($0.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.66 out of 5 stars

Medical Sector

855th out of 939 stocks

Biological Products, Except Diagnostic Industry

144th out of 159 stocks


HUMA stock logo

About Humacyte Stock (NASDAQ:HUMA)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

HUMA Stock Price History

HUMA Stock News Headlines

BCTX Jul 2024 2.500 put
Contrasting Passage Bio (NASDAQ:PASG) & Humacyte (NASDAQ:HUMA)
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
IMGN Mar 2024 32.000 put(CONTRA
HUMA Mar 2024 5.000 put
IMGN Jul 2024 29.000 call
HUMA Mar 2024 2.500 call
SHOCKING Crypto Leak Reveal Crypto's Set To SURGE
A shocking leak has revealed tech giant Microsoft plans to add crypto support to future products. If the plans in these leaked documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, and MORE. The coupling of gaming and cryptocurrency could transform digital finance as we know it. We've gathered 27 experts to share their top picks and predictions for the 2024 crypto bull run.
IMGN Apr 2024 18.000 put
Market Gets Ugly as Traders Resist Blindly Chasing Big Tech
TD Cowen Keeps Their Buy Rating on Humacyte (HUMA)
HUMAW Humacyte, Inc. Wt Exp
See More Headlines
Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
2/23/2024
Next Earnings (Estimated)
3/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:HUMA
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.75
High Stock Price Target
$15.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+79.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-11,970,000.00
Pretax Margin
-286,051.62%

Debt

Sales & Book Value

Annual Sales
$1.57 million
Book Value
$1.13 per share

Miscellaneous

Free Float
79,649,000
Market Cap
$448.46 million
Optionable
Optionable
Beta
1.41
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Laura E. Niklason M.D. (Age 61)
    Ph.D., Founder, President, CEO & Director
    Comp: $717.85k
  • Mr. Dale A. Sander (Age 64)
    CFO, Chief Corporate Development Officer & Treasurer
    Comp: $667.45k
  • Dr. Shamik J. Parikh M.D. (Age 51)
    Chief Medical Officer
    Comp: $514.72k
  • Dr. Juliana L. Blum Ph.D.
    Co-Founder & Executive Advisor
  • Dr. Heather Ledbetter Prichard Ph.D. (Age 46)
    Chief Operating Officer
    Comp: $576.44k
  • Ms. Sabrina Osborne
    Executive Vice President of Business Strategy & People
  • Mr. William John Scheessele (Age 52)
    Chief Commercial Officer
  • Mr. Harold Alterson
    Senior Vice President of Quality
  • Dr. Yang Cao M.D. (Age 58)
    Ph.D., Chief Regulatory Officer














HUMA Stock Analysis - Frequently Asked Questions

Should I buy or sell Humacyte stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HUMA shares.
View HUMA analyst ratings
or view top-rated stocks.

What is Humacyte's stock price target for 2024?

4 brokers have issued 12-month price objectives for Humacyte's stock. Their HUMA share price targets range from $3.00 to $15.00. On average, they anticipate the company's share price to reach $7.75 in the next twelve months. This suggests a possible upside of 79.0% from the stock's current price.
View analysts price targets for HUMA
or view top-rated stocks among Wall Street analysts.

How have HUMA shares performed in 2024?

Humacyte's stock was trading at $2.84 at the beginning of the year. Since then, HUMA shares have increased by 52.5% and is now trading at $4.33.
View the best growth stocks for 2024 here
.

When is Humacyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our HUMA earnings forecast
.

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). During the same quarter in the prior year, the company posted ($0.19) EPS.

What ETFs hold Humacyte's stock?

ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE).Clough Long/Short Equity ETF (CBLS).

Who are Humacyte's major shareholders?

Humacyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.02%), Northern Trust Corp (0.55%), Charles Schwab Investment Management Inc. (0.47%), GSA Capital Partners LLP (0.42%), United Asset Strategies Inc. (0.21%) and Goldman Sachs Group Inc. (0.10%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Heather Ledbetter Prichard, Laura E Niklason, Michael T Constantino and William John Scheessele.
View institutional ownership trends
.

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HUMA) was last updated on 2/23/2024 by MarketBeat.com Staff